Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

Premkumar Christadoss; Regina Henderson; Steve Keve

doi:10.1016/0090-1229(91)90022-3

Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

Premkumar Christadoss
, Regina Henderson
, Steve Keve

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

Original language	English (US)
Pages (from-to)	246-255
Number of pages	10
Journal	Clinical Immunology and Immunopathology
Volume	59
Issue number	2
DOIs	https://doi.org/10.1016/0090-1229(91)90022-3
State	Published - May 1991
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Pathology and Forensic Medicine
Immunology

Access to Document

10.1016/0090-1229(91)90022-3

Cite this

@article{0588a878418d4f17bf39434336a62b87,

title = "Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis",

abstract = "Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.",

author = "Premkumar Christadoss and Regina Henderson and Steve Keve",

note = "Funding Information: We thank Dr. Roy Korson (pathologist) for his expert histological evaluation of various samples, and Drs. Thomas T\&ton and Sheldon Cooper for reviewing the manuscript and their opinion. This work was supported by a grant from the Muscular Dystrophy Association. We also thank Barbara Cady for typing this manuscript. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1991",

month = may,

doi = "10.1016/0090-1229(91)90022-3",

language = "English (US)",

volume = "59",

pages = "246--255",

journal = "Clinical Immunology and Immunopathology",

issn = "0090-1229",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

AU - Christadoss, Premkumar

AU - Henderson, Regina

AU - Keve, Steve

N1 - Funding Information: We thank Dr. Roy Korson (pathologist) for his expert histological evaluation of various samples, and Drs. Thomas T&ton and Sheldon Cooper for reviewing the manuscript and their opinion. This work was supported by a grant from the Muscular Dystrophy Association. We also thank Barbara Cady for typing this manuscript. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1991/5

Y1 - 1991/5

N2 - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

AB - Myasthenia gravis (MG) is an autoimmune neuromuscular disease, characterized by muscle weakness and electrophysiological abnormality. No treatment which would reliably induce permanent clinical remission of MG is yet available. The therapeutic efficacy and toxic effect of daunomvcin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression.

UR - https://www.scopus.com/pages/publications/0025859317

UR - https://www.scopus.com/pages/publications/0025859317#tab=citedBy

U2 - 10.1016/0090-1229(91)90022-3

DO - 10.1016/0090-1229(91)90022-3

M3 - Article

C2 - 2009643

AN - SCOPUS:0025859317

SN - 0090-1229

VL - 59

SP - 246

EP - 255

JO - Clinical Immunology and Immunopathology

JF - Clinical Immunology and Immunopathology

IS - 2

ER -

Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this